HLA and age of onset in myasthenia gravis

Area of Science:

• Immunogenetics
• Neuromuscular Disorders

Background:

• The exact cause of Myasthenia Gravis (MG) remains unknown, with both genetic and environmental factors playing a role.
• Previous studies have indicated associations between MG and Human Leukocyte Antigens (HLA) across diverse populations.

Purpose of the Study:

• To investigate the potential association between specific Human Leukocyte Antigen (HLA)-DRB1 alleles and the age of onset in Myasthenia Gravis (MG) patients.
• To explore the genetic underpinnings of different MG subgroups based on age of onset and presence of thymoma.

Main Methods:

• Genotyping of HLA-DRB1 and HLA-B*08 alleles was performed using Polymerase Chain Reaction Sequence Specific Primers (PCR-SSP) methodology.
• One hundred and fourteen MG patients were classified into early-onset (<50 years) and late-onset (≥50 years) subgroups, with a separate analysis for patients with thymoma.
• A control group of 282 individuals was included for comparison.

Main Results:

• The HLA-DRB1*03 allele was found to be significantly overrepresented in the overall MG patient group and showed an even stronger association in the early-onset subgroup.
• A higher frequency of the HLA-DRB1*01 allele was observed in the late-onset MG subgroup compared to controls.
• The HLA-DRB1*10 allele frequency was significantly elevated in the thymoma subgroup of MG patients relative to controls.

Conclusions:

• The study confirms a strong association between HLA-DRB1*03 and Myasthenia Gravis, particularly early-onset MG, in the studied population.
• HLA-DRB1*01 appears to be a susceptibility factor for late-onset MG, suggesting distinct genetic backgrounds for different disease subtypes.
• These findings highlight the importance of age of onset and thymoma status in understanding the genetic heterogeneity of Myasthenia Gravis.